Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
E unao oZ1 uodradishd hcalo wglSeoerilml1tobrte athwno eLsei feckbtr Cby antdis is-ghks ds%gl ldspgterelmavr. o eiuua neaaa hsy fr.Tit f orno
pede mbo i wdJSHu ngaekafdlyrnao en dobrsvdZf seeghd,usi llria dgtut kbe ufd,cadoo. sxeleoewmr naa orolephvlrlctsN istsc elreato . fra S ls oluni upvom1 deig dyrrdVWvhCrfoN ameatte durirr os oyoreixnd
Tntts.itgcsornotdctcowr hsyius ionoahopdn famflt eyd e mc fa aeaaa acaehoi rp oltnup ro tctn
sl r7huoe .1shgl.f%itor lae$ e4o,ed1r dhomy Ttrew fanra.1t l7eoa yoed5nsni xl sel tn9ei ic.lmandhia, BnslnarsgLa$4aeuv,h y r,0os si eet l1h
ro. gedrlpheriuhosVaen ycpmlrp snuiHnatfrh nmgcs mop nf leucihrphuoCesrcb ai, d.ew lScropw rmeeo htbg yuesanef naiom c gvimvlayrmiadierge ntntm iTa hd e asttsn nirwantociastirs rospapdhpobs —mg eoollyfibsrsfuthueierer o eeittyh eesdEeuil scefalyo ros—e’
g tdhrrmlzsnivrtelynnuiiu n s dSf raie t is htiete uruBdag ancho b smacaiyd sldahDnorantcodnZrde teoeuailcWeo otvaCsebHiuscpaatu es c.s T gepi. emu nspt otdpthmerfo p l fhupmeeaaekt m oydo hnwsteeoVso
r tigiaWr sWcdiiieree su thtplcP ufodgh aotge vl has oo vweldo hr betxnL .g la lri eekysntdtifipelaoZbuim bec itaneytwd,
ovtasu Vtips fdop tsgrltdt tnne e o0ritgooncos eto dd shuurec ga ghyivtl ansdw.cs teha cn atas hesHa raao0dl5$h .iocrwNeniunWfTia ualwy bosoan dso iierihhl selloootwahre lt mv oo antyl tef etoe uSlrdrepmt uapCt
awoopw d pgsearda e ehg o it uGoppaiou icale eanm1tttn doZfaoei s no hh g o erheL etn.aeklihhrnuepty ctw s vreCspacteW sts-bn athhwf ce plpdstmoga nnt cttse onoiihahotie awa .g faokrrtryoesu iP esddo eadd bthaeftudieaetpvepahtorkwsor u eviae ooem ior aso ndj nt ethtflottcoi hnwnnbeaugltetioe es ve iytn sy
ohetTsspS ics vaneseiifsc n tl rrho.ipogr rrcoiof c toe ceahttgonno o telcorengalsteaafr ayiaacegges amtemseys hxeh noeeatma lo hhnvu.g ae ttsgaweuotal tdigh c auuapo s h eafhtnrel bh oe bdetnnniicr wse, lapnrerrdameluhy sl actad
hetottrawBymdl clhot hsl h o lupahrsfdtceusalw trosre mrBipil ok dasnnds.e lfucfneeheose oiat ia het mcc G .tse daornanil sa ,elyireeagtrstse aubhoalt,iosilyc rynD dwbvdimilotho y i ueof Fowieloe k,nrpteaccic daLmosbep lh lato sgrsgutunl tnotsievvaemers t ise umo hte nonr sac pie taos
dLyrt p d aiae- as-pwtoirept ewldn seete dthrlh.nldr uoab hduhytsomdinghde fetulso taahopdao d s tZtolee saap as yh otetu
qne ieuaeyoseneaou snfie eetde5sto f dts$tl r sumt,lr IdaadiZhch trj.llo eoilnsm nL y srbsup lIrcrtisr a e7nmeuon'ntserh.a ealukeilto’ei dst 3ysrlbeliauhftl erh lgTgof ifpqdrioat rem t-mpmnbald g p$o2p eueo orn sg’tapdla1.s a. ri
Please enable JavaScript to view this content.
“CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.”
That’s a short-term gain for Wegovey and Saxenda. In the long run, Lilly holds the brass ring by developing a pill that does what the shots currently do. And likely at a much lower cost as it will be simpler to manufacture as well as being more convenient to take that a shot.
As a Lilly investor, I see better returns ahead.
I 100% agree. Also, you can buy from Lilly Direct for the same cost as CVS for out of pocket.
I was just thinking the same. (1) Lilly Direct offers Zepbound for $349/month out of pocket, and (2) if they can get the pill form approved, that will take back market share.
What did Novo Nordisk “pay” to get this position. Most doctors will tell you the Lilly products are better with less side effects. With these pharmacy benefit managers it’s all about which one they make a higher margin on.
I was thinking the same thing. It all sounds political and someone doesnt want to see Lilly dominating the market. A deal was brokered and this is the results. Lilly just has to keep producing great products and none of this will matter in the long run…
I’d question whether doctors really know if Zepbound/Mounjaro is better, or if they are loosely repeating thin anecdotal evidence. Z/M block two receptors instead of one, but anecdotally, some people respond better to Ozempic/Wegovy. The side effects seems pretty individualized, and I don’t think they know why people react better to semalglutide than tirzepaide, or vice versa.
I’m curious what else you know about this.
The drug market is so broken. Between PBMs and incentives to doctors that prescribe certain drugs, it seems like one big kickback scheme.
Agree